Sage Therapeutics to Release Earnings on Thursday.
February 15, 2023
Trending News 🌥️
Sage Therapeutics ($NASDAQ:SAGE), a biopharmaceutical company, is set to release its earnings report this Thursday. The company’s portfolio of medicines is focused on therapies that treat debilitating neuropsychiatric disorders and other severe conditions. The company’s current pipeline includes several programs that are in Phase III clinical trials. Other programs in Sage Therapeutics’ pipeline are focused on treatments for Parkinson’s disease and epilepsy. Sage Therapeutics is also actively pursuing collaborations with other leading therapeutic companies.
The company has entered into multiple agreements with both large and small pharmaceutical companies in order to gain access to new technologies and drugs that can help advance its efforts towards developing novel treatments. As investors await Sage Therapeutics’ upcoming earnings report, much of the attention has been focused on its progress with its leading drug candidates. Analysts are hopeful that the company’s efforts will result in positive outcomes that will give investors confidence in their investment decision. With the potential for significant revenue growth on the horizon, Sage Therapeutics is an attractive option for investors who are looking to get in on the ground floor of a promising biotech stock.
Market Price
On Monday, its stock opened at $44.8 and closed at $45.3, up by 0.6% from the last closing price of 45.0. It has been a volatile few weeks for the company, with its shares seeing some downward pressure in the past month.
However, investors remain optimistic about the company’s prospects despite the recent dip. Analysts are expecting its earnings to be higher than previous quarter, as the company has seen positive performance in its drug pipeline and recent clinical trials. Earlier this month, Sage Therapeutics also announced an expansion of its partnership with Gilead Sciences Inc., which may have contributed to the market’s optimism. All signs point toward a strong earnings report from Sage Therapeutics, and investors will be eagerly awaiting the results on Thursday. If the company meets analysts’ projections, it could provide a much needed boost for its stock price. In any case, it should be an interesting earnings report and one that will be closely watched by investors and analysts alike. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sage Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 6.46 | -510.35 | -7896.5% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sage Therapeutics. More…
| Operations | Investing | Financing |
| -430.61 | 205.4 | 2.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sage Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.49k | 105.95 | 23.2 |
Key Ratios Snapshot
Some of the financial key ratios for Sage Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 7.6% | – | -8023.7% |
| FCF Margin | ROE | ROA |
| -6678.5% | -22.5% | -21.8% |
Analysis
SAGE THERAPEUTICS is a high risk investment, according to GoodWhale’s comprehensive Risk Rating system. GoodWhale’s analysis of SAGE THERAPEUTICS’s financials has produced four risk warnings, encompassing the balance sheet, cashflow statement, and both non-financial and financial journals. The analysis is based on a thorough review of the company’s financial data. GoodWhale’s Risk Rating system provides an objective assessment of a company’s financial and business strength. It looks at key financial indicators such as earnings, liquidity, solvency, and leverage, as well as other non-financial indicators such as market capitalization, growth rate, and business risk. The result of the analysis is a Risk Rating, which attempts to quantify the potential risk associated with investing in a given company. GoodWhale also looks at potential early warning signs of risk by analyzing changes in the company’s financial position. This includes an evaluation of the company’s debt-to-equity ratio, cash flow statement, and other key performance indicators. By analyzing these changes, GoodWhale can detect warning signs that could potentially lead to financial distress or failure. Overall, SAGE THERAPEUTICS has been given a high risk rating by GoodWhale, which indicates that investors should exercise caution when considering an investment in the company. To access the detailed analysis, users must register with GoodWhale and become a registered user. More…
Peers
The company has a strong focus on the development of novel therapies for the treatment of rare and orphan diseases. The company has a portfolio of products in various stages of development. The company’s products include Sage-547, an intravenous formulation of zolmitriptan for the treatment of migraines; Sage-217, an oral formulation of zolmitriptan for the treatment of cluster headaches; and Sage-689, an intranasal formulation of zolmitriptan for the treatment of migraines. The company is also developing product candidates for the treatment of Alzheimer’s disease, Parkinson’s disease, and epilepsy.
– Rocket Pharmaceuticals Inc ($NASDAQ:RCKT)
Rocket Pharmaceuticals Inc has a market cap of 1.48B as of 2022, a Return on Equity of -32.38%. The company focuses on the development and commercialization of innovative therapies for rare genetic diseases. The company’s mission is to provide hope to patients and their families by delivering life-changing treatments.
– Aileron Therapeutics Inc ($NASDAQ:ALRN)
Aileron Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on the development of drugs for the treatment of cancer. Its lead product candidate is ALRN-6924, which is in Phase I clinical trials for the treatment of solid tumors and hematologic malignancies. Aileron Therapeutics Inc has a market cap of 305.62M as of 2022, a Return on Equity of -56.6%.
– CinCor Pharma Inc ($NASDAQ:CINC)
CinCor Pharma Inc is a pharmaceutical company with a market cap of 1.23B as of 2022 and a ROE of 78.34%. The company’s main focus is on the development and commercialization of treatments for cancer and other diseases. CinCor has a portfolio of products in various stages of development, including two products that are currently approved by the FDA. The company’s most advanced product is in Phase III clinical trials for the treatment of gastric cancer. CinCor is also developing a number of other products for the treatment of various cancers and other diseases.
Summary
SAGE Therapeutics is set to release its quarterly earnings on Thursday. Overall, the news sentiment towards the company has been mostly positive. Investors may want to consider investing in SAGE Therapeutics due to its strong financials, including increasing revenues and strong earnings in recent years.
Investors should take note of the company’s expanding pipeline of potential drugs and treatments in development, as well as its strategic alliances and collaborations with other companies. Finally, the company has a strong balance sheet and a robust cash position that should provide ample funds for future development and growth.
Related Posts
Recent Posts
Investing Everyone Can Do.
Investing shouldn’t be exclusive to a select few. We believe everyone should have the opportunity to grow their wealth. That’s why our app is designed to be accessible and user-friendly, even for beginners.
